As of November 6, 2026, 2 holders' latest Schedule 13D or 13G filings report owning 5% or more of 89bio, Inc. The largest reported stake is The Vanguard Group's, at 5.64%. 10 filings are on record since July 29, 2025 (Schedule 13G, July 29, 2025).
Sell to companies like 89bio, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: Deep Track Capital, LP · Sole voting: 0 · Shared voting: 0 · Sole dispositive: 0 · Shared dispositive: 0 · SCHEDULE 13G/A, 2026-02-13
- · Reporting person: Pentwater Capital Management LP · Sole voting: 0 · Shared voting: 0 · Sole dispositive: 0 · Shared dispositive: 0 · SCHEDULE 13G, 2025-11-14
- · Holder: Deep Track Capital, LP · Percent: 6.31% · SCHEDULE 13G/A
- · Reporting person: Suvretta Capital Management, LLC · Sole voting: 0 · Shared voting: 8,280,000 · Sole dispositive: 0 · Shared dispositive: 8,280,000 · SCHEDULE 13G/A, 2025-11-13
- · Holder: RA Capital Management, L.P. · Percent: 0% · SCHEDULE 13D/A
89bio, Inc. has 10 Schedule 13D or 13G filings on record since 2025-07-29. 2 holders' latest filing reports 5% or more of common stock, par value $0.001 per share. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| The Vanguard Group | 5.64% | 8,242,154 | SCHEDULE 13G, 2025-07-29 | 2025-06-30 |
| Suvretta Capital Management, LLC | 5.6% | 8,280,000 | SCHEDULE 13G/A, 2025-11-13 | 2025-09-30 |
| Janus Henderson Group Plc | 3.6% | 5,378,185 | SCHEDULE 13G/A, 2025-10-07 | 2025-09-30 |
| Adage Capital Management, L.P. | 0% | 0 | SCHEDULE 13D/A, 2025-10-31 | 2025-10-29 |
| RA Capital Management, L.P. | 0% | 0 | SCHEDULE 13D/A, 2025-11-03 | 2025-10-30 |
| Pentwater Capital Management LP | 0% | 0 | SCHEDULE 13G, 2025-11-14 | 2025-09-30 |
| Deep Track Capital, LP | 0% | 0 | SCHEDULE 13G/A, 2026-02-13 | 2025-12-31 |
Holding shares or following this stake? See who's behind 89bio, Inc. and the warning signs.
Free to see. No signup.
Keep reading
More on 89bio, Inc. and the records around it.
89bio, Inc. elsewhere on the record
- Acquisition Oct 2025
Companies that share a holder
- Pentwater Capital Management LP also filed stake reports on 20 other companies: AMC Entertainment Holdings, Inc. (Aug 2026), Caesars Entertainment, Inc. (Aug 2026), Centessa Pharmaceuticals plc (Aug 2026)
- SUVRETTA CAPITAL MANAGEMENT, LLC also filed stake reports on 22 other companies: Veradermics, Inc (Aug 2026), Abeona Therapeutics Inc. (Aug 2026), Fulcrum Therapeutics, Inc. (Aug 2026)
- Deep Track Capital, LP also filed stake reports on 59 other companies: Alector, Inc. (Oct 2026), TCGX Acquisition Corp. II (Oct 2026), Frazier Life Sciences Acquisition Corp. II (Oct 2026)
Watch 89bio, Inc.
Get an email when 89bio, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on 89bio, Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on 89bio, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on 89bio, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
11 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| Suvretta Capital Management, LLC | 0 | 8,280,000 | 0 | 8,280,000 | SCHEDULE 13G/A, 2025-11-13 |
| Averill Master Fund, Ltd. | 0 | 7,135,599 | 0 | 7,135,599 | SCHEDULE 13G/A, 2025-11-13 |
| Aaron Cowen | 0 | 8,280,000 | 0 | 8,280,000 | SCHEDULE 13G/A, 2025-11-13 |
| Pentwater Capital Management LP | 0 | 0 | 0 | 0 | SCHEDULE 13G, 2025-11-14 |
| Matthew Halbower | 0 | 0 | 0 | 0 | SCHEDULE 13G, 2025-11-14 |
| Deep Track Capital, LP | 0 | 0 | 0 | 0 | SCHEDULE 13G/A, 2026-02-13 |
| Deep Track Biotechnology Master Fund, Ltd. | 0 | 0 | 0 | 0 | SCHEDULE 13G/A, 2026-02-13 |
| David Kroin | 0 | 0 | 0 | 0 | SCHEDULE 13G/A, 2026-02-13 |
The latest filing names 89bio, Inc., with its principal executive office as 655 Montgomery Street, Suite 1500, San Francisco, CA 94111 (SCHEDULE 13G/A, 2026-02-13).
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-07-29 | The Vanguard Group | 5.64% | SCHEDULE 13G |
| 2025-08-14 | Janus Henderson Group Plc | 14.2% | SCHEDULE 13G/A |
| 2025-10-03 | Adage Capital Management, L.P. | 6.13% | SCHEDULE 13D |
| 2025-10-07 | Janus Henderson Group Plc | 3.6% | SCHEDULE 13G/A |
| 2025-10-31 | Adage Capital Management, L.P. | 0% | SCHEDULE 13D/A |
| 2025-11-03 | RA Capital Management, L.P. | 0% | SCHEDULE 13D/A |
| 2025-11-13 | Suvretta Capital Management, LLC | 5.6% | SCHEDULE 13G/A |
| 2025-11-14 | Pentwater Capital Management LP | 0% | SCHEDULE 13G |
| 2025-11-14 | Deep Track Capital, LP | 6.31% | SCHEDULE 13G/A |
| 2026-02-13 | Deep Track Capital, LP | 0% | SCHEDULE 13G/A |
Questions about who owns 89bio, Inc.
Who owns 89bio, Inc.?
On this page, 2 holders' latest ownership filings report 5% or more of 89bio, Inc.: The Vanguard Group (5.64%, Schedule 13G, filed 2025-07-29) and Suvretta Capital Management, LLC (5.6%, Schedule 13G/A, filed 2025-11-13).
Who are the largest shareholders of 89bio, Inc.?
By the share each holder's latest filing reports, the largest holders of 89bio, Inc. on this page are The Vanguard Group (5.64%) and Suvretta Capital Management, LLC (5.6%).
When did The Vanguard Group buy into 89bio, Inc.?
The filings give report dates, not purchase dates. The earliest filing from The Vanguard Group on this page is the Schedule 13G, filed 2025-07-29, reporting 5.64%.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 10 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Also on the record for 89bio, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| October 1, 2025 | Acquired by Roche Holdings, Inc. | — | Acquisition | Source |
Tools for this story
Each opens in a new tab, filled in for 89bio, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.